Abstract
A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Hepatology |
Vol/bind | 69 |
Udgave nummer | 5 |
Sider (fra-til) | 2300 |
Antal sider | 1 |
ISSN | 0270-9139 |
DOI |
|
Status | Udgivet - maj 2019 |